On (b)(6) 2017, a patient underwent a staged convergent procedure.Post-procedure, the patients¿ blood pressure remained unstable but the convergent procedure itself was unremarkable with no product malfunction encountered.The patient continued to experience a-fib post-procedure and on (b)(6) 2017, underwent the ep portion of the procedure and underwent extensive ablations.The procedure was completed without any complications and patient was anticoagulated with coumadin.On (b)(6) 2017, patient developed hemoptysis and was taken to icu where a ct scan performed ruled out perforation and fistula.The patient¿s condition worsened and he expired on (b)(6) 2017.The patient¿s other co-morbidities included cocaine abuse.There were no procedural complications or device malfunction noted.On (b)(6) 2017 detailing of events was communicated to the manufacturer.
|